<DOC>
	<DOCNO>NCT03009526</DOCNO>
	<brief_summary>This study aim compare efficacy monthly IPTp-DP monthly IPTp-SP determine IPTp-DP associate reduction malaria infection delivery among HIV-negative woman area high level SP resistance Malawi .</brief_summary>
	<brief_title>Efficacy Safety IPTp-DP Versus IPTp-SP Malawi</brief_title>
	<detailed_description>Problem study Malaria pregnancy ( MiP ) due Plasmodium falciparum infection major cause maternal morbidity poor birth outcomes malaria-endemic country . Pregnant woman increase risk frequent severe malaria infection non-pregnant woman . Intermittent preventive treatment pregnancy ( IPTp ) sulfadoxine-pyrimethamine ( SP ) , involve administration treatment dose SP antenatal visit second third trimester pregnancy , least one month apart , irrespective malaria parasitemia , currently recommend woman , except HIV positive woman take daily cotrimoxazole prophylaxis , area stable moderate high transmission malaria . SP drug currently use IPTp . Due increase resistance SP , longer use treatment symptomatic malaria , however , IPTp-SP remain effective even area SP resistance child five ( determine vivo efficacy study ) 26 % , continue use IPTp country SP longer recommend treat symptomatic malaria . However , IPTp-SP become controversial give recent data northern Tanzania Malawi demonstrate high rate resistance , IPTp-SP may longer effective . Alternative drug could replace SP test ; mefloquine , azithromycin-chloroquine , amodiaquine abandon option due poor tolerability among pregnant woman . Dihydroartemisinin-Piperaquine ( DP ) remain attractive option long half-life piperaquine ( PQ ) demonstrate efficacy , safety , tolerability pregnancy . Recent study Kenya Uganda use DP IPTp demonstrate significant reduction prevalence malaria throughout pregnancy time delivery . However , clear benefit term improve neonatal outcome . Additional study therefore need determine impact switch IPTp-SP IPTp-DP . Study aim Primary objective To compare efficacy monthly IPTp-DP monthly IPTp-SP determine IPTp-DP associate reduction malaria infection delivery among HIV-negative woman area high level SP resistance Malawi . Secondary objectives - To determine IPTp-DP result decrease fetal morbidity compare IPTp-SP , fetal morbidity define composite following : Preterm birth ( &lt; 37 week gestation ) , low birth weight ( LBW ) ( &lt; 2,500 gram ) , small gestational age ( SGA ) . - To evaluate tolerability safety IPTp-DP second third trimester pregnancy , include assessment cardiac risk , measure change QTc interval baseline successive dose . - To compare frequency adverse event fetal congenital malformation IPTp-DP IPTp-SP . - To assess SP DP affect maternal intestinal vaginal microbiome . Methodology Open-label , 2 arm randomize controlled superiority trial compare efficacy safety IPTp-DP IPTp-SP Malawi . The trial design show 60 % decrease malaria infection delivery among HIV-negative woman gravidity IPTp-DP use instead IPTp-SP . Expected finding dissemination It expect area high SP resistance , IPTp-DP superior IPTp-SP decreasing malaria infection delivery . In addition , anticipated DP well-tolerated among pregnant woman fetal outcomes well IPTp-SP .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Dihydroartemisinin</mesh_term>
	<mesh_term>Fanasil , pyrimethamine drug combination</mesh_term>
	<mesh_term>Piperaquine</mesh_term>
	<mesh_term>Sulfadoxine</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Pyrimethamine</mesh_term>
	<criteria>Viable singleton pregnancy Gestational age ≤28 complete week ( 28 6/7 ) fundal height/ultrasound Maternal age ≥16 year No history IPTp use pregnancy Willing participate complete study schedule , include laboratory study delivery labor ward study clinic hospital Willing sign thumb print inform consent Resident study area intend stay area duration followup HIVnegative enrolment HIVpositive unknown Multiple gestation Highrisk pregnancy , include preexist illness likely cause complication pregnancy ( hypertension , diabetes , asthma , epilepsy , renal disease , liver disease , fistula repair , leg spine deformity ) Severe anemia require blood transfusion ( Hb &lt; 7.0 g/dL ) enrolment Known allergy previous adverse reaction study drug Previous inclusion study Participating malaria intervention study Known suspect cardiac disease Corrected QT interval ( QTcF ) great 450 ms baseline Patients take follow drug : Antimicrobial agent follow class ( systemic use ) : Macrolides ( e.g . erythromycin , clarithromycin , azithromycin , roxithromycin ) Fluoroquinolones ( e.g. , levofloxacin , moxifloxacin , sparfloxacin ) Pentamidine Antiarrhythmic agent ( e.g . amiodarone , sotalol ) Antihistamines ( e.g . promethazine ) Antifungals ( systemic ) : ketoconazole , fluconazole , itraconazole Antiretrovirals : Saquinavir Diuretics ( e.g . hydrochlorothiazide , furosemide ) Antipsychotics ( neuroleptic ) : haloperidol , thioridazine Antidepressants : imipramine , citalopram , escitalopram Antiemetics : domperidone , chlorpromazine , ondansetron</criteria>
	<gender>Female</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Malaria</keyword>
	<keyword>Pregnancy</keyword>
	<keyword>Malawi</keyword>
	<keyword>Intermittent preventive treatment</keyword>
	<keyword>dihydroartemisinin-piperaquine</keyword>
	<keyword>sulfadoxine-pyrimethamine</keyword>
</DOC>